SCHEMBL5882012

SCHEMBL5882012

CCCCS(=O)(=O)NC(=O)c1ccc2ccn(Cc3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 0.64
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
CPT1A P50416 1/20 0.42
CPT1B Q92523 1/20 0.42
PTGDR Q13258 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
PTGER1 P34995 1/20 0.40
PTGER4 P35408 1/20 0.40
PTGER3 P43115 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881819 0.93 PPARG (0.62) PPARGHDAC3HDAC1HDAC2HDAC11
SCHEMBL5881969 0.84 PPARG (0.71) PPARGHDAC1HDAC2HDAC8HDAC6
SCHEMBL5882185 0.83 PPARG (0.67) PPARGHDAC1HDAC8HDAC6
SCHEMBL1608388 0.83 HDAC8 (0.58) PPARGHDAC3HDAC4HDAC1HDAC7
SCHEMBL5882208 0.81 PPARG (0.75) PPARGHDAC1HDAC2HDAC8HDAC6
SCHEMBL1178271 0.81 PPARG (0.79) PPARG
SCHEMBL1160177 0.81 PPARG (0.95) PPARGHDAC3HDAC4HDAC1HDAC7
SCHEMBL5882002 0.81 PPARG (0.66) PPARGPTGER3
SCHEMBL1160358 0.80 PPARG (0.78) PPARG
SCHEMBL6301804 0.80 PPARG (0.67) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PPARG 4239/4885HDAC3 1384/4885HDAC4 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.